$RPRX with only 22m in the float could still be a dip and rip they will need to repeat phaseIII studies for their enclomiphene drug however they're still planning on submitting to the EMA (european version of the FDA 1st quarter of 2016) it was trading around 8 during the first letter from the FDA currently 1.79 and green for the day.